FDA grants praliciguat Fast Track Designation for HFpEF


The Food and Drug Administration has granted praliciguat Fast Track Designation for treatment of patients with heart failure with preserved ejection fraction (HFpEF), according to its developer Ironwood.

FDA icon

A phase 2, randomized, double-blind, placebo-controlled trial is currently enrolling patients to evaluate praliciguat as a treatment for HFpEF. The trial aims to enroll about 175 patients and intends to evaluate safety and efficacy, and topline data is expected later in 2019.

Praliciguat is an oral, once-daily, soluble guanylate cyclase (sGC) stimulator. It is being studied in patients with diabetic nephropathy and in patients with HFpEF. The condition affects an estimated 3 million Americans, but there are no approved therapies at this time to treat it; however, praliciguat may have the potential to treat the underlying causes by improving nitric oxide signaling, according to the press release from Ironwood.

Recommended Reading

Rivaroxaban no help for heart failure outcomes
MDedge Cardiology
Declining lung function linked to heart failure, stroke
MDedge Cardiology
ATTR-ACT shows treatment breakthrough in amyloid cardiomyopathy
MDedge Cardiology
Danish endocarditis strategy halved hospital days
MDedge Cardiology
Pregnancy boosts cardiac disease mortality nearly 100-fold
MDedge Cardiology